Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.54 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 6/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4325111 | 0.88 | DPP4 (0.51) | PARP1NR1H2NR1H3DPP4CA1 | |
| SCHEMBL2086518 | 0.87 | PARP1 (0.50) | PARP1NR1H2NR1H3DPP4CA1 | |
| SCHEMBL874154 | 0.87 | PARP1 (0.50) | PARP1NR1H2NR1H3DPP4DPP7 | |
| SCHEMBL4325120 | 0.86 | PARP1 (0.49) | PARP1NR1H2NR1H3DPP4DPP7 | |
| SCHEMBL4325154 | 0.85 | PARP1 (0.48) | PARP1NR1H2NR1H3DPP4CA1 | |
| SCHEMBL873429 | 0.85 | PARP1 (0.54) | PARP1NR1H2NR1H3DPP4CA1 | |
| SCHEMBL873458 | 0.85 | PARP1 (0.54) | PARP1NR1H2NR1H3DPP4CA1 | |
| SCHEMBL4309187 | 0.85 | PARP1 (0.54) | PARP1NR1H2NR1H3DPP4CA1 | |
| SCHEMBL27901916 | 0.83 | DPP4 (0.47) | DPP4CA1CA2CA4CA9 | |
| SCHEMBL874366 | 0.82 | POLB (0.49) | PARP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624200-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-04-18 | — | — | US | disclosed |
| EP-1989188-B1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2015-07-22 | — | — | EP | disclosed |
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. | 2015-03-26 | — | — | US | disclosed |
| US-8927546-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-01-06 | — | — | US | disclosed |
| EP-2562168-B1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2014-04-16 | — | — | EP | disclosed |
| US-20140038945-A1 | PIPERAZINE PDE4 INHIBITORS AND USES THEREOF | DART NEUROSCIENCE (CAYMAN) LTD (KY) | 2014-02-06 | — | — | US | disclosed |
| EP-2643000-A2 | THERAPEUTIC PIPERAZINES | Dart Neuroscience (Cayman) Ltd (KY) | 2013-10-02 | — | — | EP | disclosed |
| US-8501745-B2 | Piperazine PDE4 inhibitors and uses thereof | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-08-06 | — | — | US | disclosed |
| EP-2562168-A1 | Therapeutic piperazines as PDE4 inhibitors | Helicon Therapeutics, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| US-8338405-B2 | Therapeutic piperazines | DART NEUROSCIENCE LLC (US) | 2012-12-25 | — | — | US | disclosed |
| US-7829713-B2 | Therapeutic piperazines | HELICON THERAPEUTICS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| EP-1871765-B1 | 3-(INDAZOL-5-YL)-(1,2,4)TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORP (US) | 2009-12-09 | — | — | EP | disclosed |
| US-7528132-B2 | immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease; indazolyl [1,2,4]triazine compounds | SCHERING CORPORATION (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1989188-A1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | Helicon Therapeutics, Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| CN-101146796-A | 3-(indazol-5-yl)-(1,2,4)triazine derivatives and related compounds as protein kinase inhibitors for the treatment of cancer | SCHERING CORP (US) | 2008-03-19 | — | — | CN | disclosed |
| US-20080004257-A1 | Kinase inhibitors | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
| EP-1871765-A2 | 3-(INDAZOL-5-YL)-(1,2,4)TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2007100852-A1 | THERAPEUTIC PIPERAZINES AS PDE4 INHIBITORS | HELICON THERAPEUTICS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070203124-A1 | Therapeutic Piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2007-08-30 | — | — | US | disclosed |
| WO-2006081230-A2 | 3-(INDAZOL-5-YL)-(1,2, 4) TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | PARP1 748/4885NR1H2 835/4885NR1H3 1194/4885 |
| US-20070203124-A1 | Therapeutic Piperazines | PDE4A, PDE4B, PDE12 | PARP1 1492/4885NR1H2 744/4885NR1H3 1001/4885 |
| US-20080004257-A1 | Kinase inhibitors | MAP3K1, MAP3K13, MAP3K6 | PARP1 1556/4885NR1H2 1656/4885NR1H3 1667/4885 |
| US-20140038945-A1 | PIPERAZINE PDE4 INHIBITORS AND USES THEREOF | PDE4A, PDE12, PDE4B | PARP1 915/4885NR1H2 1835/4885NR1H3 2197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.